193 related articles for article (PubMed ID: 26786927)
1. Impaired c-Met Receptor Degradation Mediated by MET Exon 14 Mutations in Non-Small-Cell Lung Cancer.
Awad MM
J Clin Oncol; 2016 Mar; 34(8):879-81. PubMed ID: 26786927
[No Abstract] [Full Text] [Related]
2. c-MET Overexpression as a Poor Predictor of MET Amplifications or Exon 14 Mutations in Lung Sarcomatoid Carcinomas.
Mignard X; Ruppert AM; Antoine M; Vasseur J; Girard N; Mazières J; Moro-Sibilot D; Fallet V; Rabbe N; Thivolet-Bejui F; Rouquette I; Lantuejoul S; Cortot A; Saffroy R; Cadranel J; Lemoine A; Wislez M
J Thorac Oncol; 2018 Dec; 13(12):1962-1967. PubMed ID: 30149144
[TBL] [Abstract][Full Text] [Related]
3. MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression.
Awad MM; Oxnard GR; Jackman DM; Savukoski DO; Hall D; Shivdasani P; Heng JC; Dahlberg SE; Jänne PA; Verma S; Christensen J; Hammerman PS; Sholl LM
J Clin Oncol; 2016 Mar; 34(7):721-30. PubMed ID: 26729443
[TBL] [Abstract][Full Text] [Related]
4. Genetic screening and molecular characterization of MET alterations in non-small cell lung cancer.
Saigi M; McLeer-Florin A; Pros E; Nadal E; Brambilla E; Sanchez-Cespedes M
Clin Transl Oncol; 2018 Jul; 20(7):881-888. PubMed ID: 29139039
[TBL] [Abstract][Full Text] [Related]
5. Distinct MET Protein Localization Associated With MET Exon 14 Mutation Types in Patients With Non-small-cell Lung Cancer.
Qiu T; Li W; Zhang T; Xing P; Huang W; Wang B; Chu L; Guo L; Liu X; Li Y; Ying J; Li J
Clin Lung Cancer; 2018 Jul; 19(4):e391-e398. PubMed ID: 29338938
[TBL] [Abstract][Full Text] [Related]
6. [MET exon 14 mutation, new target in lung sarcomatoid carcinoma].
Domblides C; Cortot A; Wislez M
Bull Cancer; 2015 Dec; 102(12):966. PubMed ID: 27064153
[No Abstract] [Full Text] [Related]
7. MET Exon 14 Alterations in Lung Cancer: Exon Skipping Extends Half-Life.
Drilon A
Clin Cancer Res; 2016 Jun; 22(12):2832-4. PubMed ID: 27009743
[TBL] [Abstract][Full Text] [Related]
8. The Unique Characteristics of MET Exon 14 Mutation in Chinese Patients with NSCLC.
Liu SY; Gou LY; Li AN; Lou NN; Gao HF; Su J; Yang JJ; Zhang XC; Shao Y; Dong ZY; Zhou Q; Zhong WZ; Wu YL
J Thorac Oncol; 2016 Sep; 11(9):1503-10. PubMed ID: 27257131
[TBL] [Abstract][Full Text] [Related]
9. Expression of MET and SOX2 genes in non-small cell lung carcinoma with EGFR mutation.
Cai YR; Zhang HQ; Qu Y; Mu J; Zhao D; Zhou LJ; Yan H; Ye JW; Liu Y
Oncol Rep; 2011 Oct; 26(4):877-85. PubMed ID: 21687954
[TBL] [Abstract][Full Text] [Related]
10. MET tyrosine kinase inhibitor crizotinib (PF-02341066) shows differential antitumor effects in non-small cell lung cancer according to MET alterations.
Tanizaki J; Okamoto I; Okamoto K; Takezawa K; Kuwata K; Yamaguchi H; Nakagawa K
J Thorac Oncol; 2011 Oct; 6(10):1624-31. PubMed ID: 21716144
[TBL] [Abstract][Full Text] [Related]
11.
Socinski MA; Pennell NA; Davies KD
JCO Precis Oncol; 2021; 5():. PubMed ID: 34036238
[No Abstract] [Full Text] [Related]
12. MET exon 14 mutations as targets in routine molecular analysis of primary sarcomatoid carcinoma of the lung.
Saffroy R; Fallet V; Girard N; Mazieres J; Sibilot DM; Lantuejoul S; Rouquette I; Thivolet-Bejui F; Vieira T; Antoine M; Cadranel J; Lemoine A; Wislez M
Oncotarget; 2017 Jun; 8(26):42428-42437. PubMed ID: 28418914
[TBL] [Abstract][Full Text] [Related]
13. Impact of bevacizumab in combination with erlotinib on EGFR-mutated non-small cell lung cancer xenograft models with T790M mutation or MET amplification.
Furugaki K; Fukumura J; Iwai T; Yorozu K; Kurasawa M; Yanagisawa M; Moriya Y; Yamamoto K; Suda K; Mizuuchi H; Mitsudomi T; Harada N
Int J Cancer; 2016 Feb; 138(4):1024-32. PubMed ID: 26370161
[TBL] [Abstract][Full Text] [Related]
14. Optimization of Routine Testing for MET Exon 14 Splice Site Mutations in NSCLC Patients.
Descarpentries C; Leprêtre F; Escande F; Kherrouche Z; Figeac M; Sebda S; Baldacci S; Grégoire V; Jamme P; Copin MC; Tulasne D; Cortot AB
J Thorac Oncol; 2018 Dec; 13(12):1873-1883. PubMed ID: 30195702
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA-200a Targets EGFR and c-Met to Inhibit Migration, Invasion, and Gefitinib Resistance in Non-Small Cell Lung Cancer.
Zhen Q; Liu J; Gao L; Liu J; Wang R; Chu W; Zhang Y; Tan G; Zhao X; Lv B
Cytogenet Genome Res; 2015; 146(1):1-8. PubMed ID: 26184032
[TBL] [Abstract][Full Text] [Related]
16. c-MET/phospho-MET protein expression and MET gene copy number in non-small cell lung carcinomas.
Tsuta K; Kozu Y; Mimae T; Yoshida A; Kohno T; Sekine I; Tamura T; Asamura H; Furuta K; Tsuda H
J Thorac Oncol; 2012 Feb; 7(2):331-9. PubMed ID: 22198430
[TBL] [Abstract][Full Text] [Related]
17. [MET exon 14 splicing sites mutations: A new therapeutic opportunity in lung cancer].
Baldacci S; Kherrouche Z; Descarpentries C; Wislez M; Dansin E; Furlan A; Tulasne D; Cortot AB
Rev Mal Respir; 2018 Oct; 35(8):796-812. PubMed ID: 30174236
[TBL] [Abstract][Full Text] [Related]
18. Targeting the MET gene for the treatment of non-small-cell lung cancer.
Gelsomino F; Facchinetti F; Haspinger ER; Garassino MC; Trusolino L; De Braud F; Tiseo M
Crit Rev Oncol Hematol; 2014 Feb; 89(2):284-99. PubMed ID: 24355409
[TBL] [Abstract][Full Text] [Related]
19. Multikinase Inhibitor Crizotinib Is Active in
Cancer Discov; 2020 Mar; 10(3):337. PubMed ID: 31980568
[TBL] [Abstract][Full Text] [Related]
20. NSCLC patients with MET non-exon-14 mutations rather than MET exon 14 mutations response to immune checkpoint inhibitors.
Li X; Liu J; Guo M; Cai H; Chen D
Lung Cancer; 2021 Feb; 152():202-204. PubMed ID: 33422364
[No Abstract] [Full Text] [Related]
[Next] [New Search]
